Several cancer therapeutic agents may modulate death receptor expression by tumor cells including DNA damaging agents [81], histone deacetylase (HDAC) inhibitors [82], proteasome inhibitors [83] and cyclooxygenase-2 (COX2) inhibitors [84]. This evidence concerns the gene PTGS2 and neoplasm.